Medically reviewed by Drugs.com. Last updated on Aug 19, 2019.
(zink KLOR ide)
Excipient information presented when available (limited, particularly for generics); consult specific product labeling.
Solution, Intravenous [preservative free]:
Generic: 1 mg/mL (10 mL)
- Trace Element
Storage sites are liver and skeletal muscle; serum levels do not adequately reflect whole-body zinc status
Primarily in feces (Anderson 1998)
55% bound to albumin; 40% bound to alpha 1-macroglobulin
Use: Labeled Indications
Trace element added to parenteral nutrition (PN) to prevent deficiency
Parenteral nutrition, maintenance requirement: IV: Note: Dosage expressed in terms of elemental zinc:
Acute metabolic states: 4.5 to 6 mg/day
Metabolically stable: 2.5 to 5 mg/day (ASPEN [Vanek 2012])
Stable with fluid loss from small bowel: 12.2 mg zinc/L TPN or 17.1 mg zinc/kg (added to 1000 mL IV fluids) of stool or ileostomy output
Note: Clinical response from deficiency may not occur for up to 6 to 8 weeks.
Refer to adult dosing.
Note: Dosages may be presented in units of mcg or mg, use caution to ensure correct units. Clinical response may not occur for up to 6 to 8 weeks:
Parenteral nutrition, maintenance requirement: IV: Note: Dosage expressed in terms of elemental zinc; higher doses may be needed if impaired intestinal absorption or an excessive loss of zinc (eg, excessive, prolonged diarrhea, high-output intestinal fistula, burns)
Age-directed dosing (ASPEN [Vanek 2012]):
Infants <3 months: 250 mcg/kg/day
Infants ≥3 months: 50 mcg/kg/day
Children: 50 mcg/kg/day; maximum daily dose: 5,000 mcg/day
Weight-directed dosing (ASPEN [Mirtallo 2004]):
Infants <10 kg: 50 to 250 mcg/kg/day
Children 10 to 40 kg: 50 to 125 mcg/kg/day; maximum daily dose: 5,000 mcg/day
Children and Adolescents >40 kg: 2,000 to 5,000 mcg/day
Solution for IV injection: Administer after dilution in volume of fluid ≥100 mL
Store intact vial at 20°C to 25°C (68°F to 77°F).
Dolutegravir: Zinc Salts may decrease the serum concentration of Dolutegravir. Management: Administer dolutegravir at least 2 hours before or 6 hours after oral zinc salts. Administer the dolutegravir/rilpivirine combination product at least 4 hours before or 6 hours after oral zinc salts. Consider therapy modification
<1%, postmarketing, and/or case reports: Dyspepsia, hypotension, jaundice, leukopenia, nausea, neutropenia, pulmonary edema, vomiting
• Renal impairment: Use with caution in patients with renal impairment.
Concurrent drug therapy issues:
• Copper: IV administration of zinc without copper may cause a decrease in copper serum concentrations.
Dosage form specific issues:
• Aluminum: The parenteral product may contain aluminum; toxic aluminum concentrations may be seen with high doses, prolonged use, or renal dysfunction. Premature neonates are at higher risk due to immature renal function and aluminum intake from other parenteral sources. Parenteral aluminum exposure of >4 to 5 mcg/kg/day is associated with CNS and bone toxicity; tissue loading may occur at lower doses (Federal Register, 2002). See manufacturer’s labeling.
Patients on parenteral nutrition or chronic therapy should have periodic serum copper and serum zinc levels; alkaline phosphatase, taste acuity, mental depression
Pregnancy Risk Factor
Zinc crosses the placenta and can be measured in the cord blood and placenta. Fetal concentrations are regulated by the placenta (de Moraes, 2011).
• Discuss specific use of drug and side effects with patient as it relates to treatment. (HCAHPS: During this hospital stay, were you given any medicine that you had not taken before? Before giving you any new medicine, how often did hospital staff tell you what the medicine was for? How often did hospital staff describe possible side effects in a way you could understand?)
• Educate patient about signs of a significant reaction (eg, wheezing; chest tightness; fever; itching; bad cough; blue skin color; seizures; or swelling of face, lips, tongue, or throat). Note: This is not a comprehensive list of all side effects. Patient should consult prescriber for additional questions.
Intended Use and Disclaimer: Should not be printed and given to patients. This information is intended to serve as a concise initial reference for health care professionals to use when discussing medications with a patient. You must ultimately rely on your own discretion, experience, and judgment in diagnosing, treating, and advising patients.